Astra and Daiichi beat Gilead to the punch, at least in one setting.
ApexOnco Front Page
Recent articles
Silevertinib efficacy comes close to firmonertinib’s, but toxicity is a new worry.
Amgen and Zai Lab’s FGFR2b antibody shows no benefit at the two-year mark.
Response rates with INCB161734 in pancreatic cancer look in line with Revolution.
A quartet of failed tiragolumab trials featured at ESMO over the weekend.
Harmoni-6 succeeds in first-line lung cancer, but the focus is on changes to Harmoni-3.
The Stellar-303 trial of zanzalintinib hits, but the discussant asks for more data and flags toxicity.
The first TUB-040 data come just after Tubulis raised €308m.